Cargando…

Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets

More than two decades have elapsed since the publication of the first genome sequence of Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine gene essentiality in the pathogen. Despite this, target-based approaches have not yielded drugs that have progressed to cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Sangmi, Trifonov, Lena, Yadav, Veena D., Barry, Clifton E., Boshoff, Helena I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005628/ https://www.ncbi.nlm.nih.gov/pubmed/33791235 http://dx.doi.org/10.3389/fcimb.2021.611304

Ejemplares similares

Editorial: Drug-resistant Mycobacterium tuberculosis
por: Boshoff, Helena I. M., et al.
Publicado: (2023)

Synthesis and Structure–Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents
por: Yadav, Veena D., et al.
Publicado: (2023)

Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and Approaches
por: Singh, Vinayak
Publicado: (2021)

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
por: Bhagwat, Amala, et al.
Publicado: (2022)

The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis
por: Huang, Lu, et al.
Publicado: (2018)

Editorial: From Apicomplexan Genes to Drug Discovery
por: Wunderlich, Gerhard, et al.
Publicado: (2021)

Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis
por: Chengalroyen, Melissa D., et al.
Publicado: (2020)

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
por: Khan, Shaheen, et al.
Publicado: (2020)

Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase
por: Wang, Chao, et al.
Publicado: (2022)

Failing upwards: Genetics-based strategies to improve antibiotic discovery and efficacy in Mycobacterium tuberculosis
por: Tomasi, Francesca G., et al.
Publicado: (2022)

Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China
por: Wu, Xiaocui, et al.
Publicado: (2019)

Re-Envisioning Anti-Apicomplexan Parasite Drug Discovery Approaches
por: Rangel, Gabriel W., et al.
Publicado: (2021)

Exploring the “Multiple-Hit Hypothesis” of Neurodegenerative Disease: Bacterial Infection Comes Up to Bat
por: Patrick, Kristin L., et al.
Publicado: (2019)

Transcriptional regulation and drug resistance in Mycobacterium tuberculosis
por: Miotto, Paolo, et al.
Publicado: (2022)

The evolving biology of Mycobacterium tuberculosis drug resistance
por: Jones, Richard M., et al.
Publicado: (2022)

Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis
por: Wu, Chunli, et al.
Publicado: (2023)

Understanding the contribution of metabolism to Mycobacterium tuberculosis drug tolerance
por: Samuels, Amanda N., et al.
Publicado: (2022)

Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis
por: Poulton, Nicholas C., et al.
Publicado: (2022)

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era
por: Nimmo, Camus, et al.
Publicado: (2022)

Trends and challenges of multi-drug resistance in childhood tuberculosis
por: Zhuang, Zengfang, et al.
Publicado: (2023)

Anti-parasitic drug discovery against Babesia microti by natural compounds: an extensive computational drug design approach
por: Akash, Shopnil, et al.
Publicado: (2023)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Drug Discovery and Repurposing Inhibits a Major Gut Pathogen-Derived Oncogenic Toxin
por: Metz, Paul, et al.
Publicado: (2019)

Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management
por: Liebenberg, Dale, et al.
Publicado: (2022)

Anti-viral drug discovery against monkeypox and smallpox infection by natural curcumin derivatives: A Computational drug design approach
por: Akash, Shopnil, et al.
Publicado: (2023)

Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis
por: Eoh, Hyungjin, et al.
Publicado: (2022)

Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis
por: Greenstein, Talia, et al.
Publicado: (2023)

Corrigendum: Anti-viral drug discovery against monkeypox and smallpox infection by natural curcumin derivatives: a computational drug design approach
por: Akash, Shopnil, et al.
Publicado: (2023)

Mycobacterium tuberculosis functional genetic diversity, altered drug sensitivity, and precision medicine
por: Stanley, Sydney, et al.
Publicado: (2022)

Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host
por: Schami, Alyssa, et al.
Publicado: (2023)

Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular Mycobacterium tuberculosis
por: Rienksma, Rienk A., et al.
Publicado: (2019)

Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis
por: McNeil, Matthew B., et al.
Publicado: (2022)

Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design
por: Rudraraju, Reshma S., et al.
Publicado: (2022)

Detection of differentially culturable tubercle bacteria in sputum from drug-resistant tuberculosis patients
por: Gordhan, Bhavna G., et al.
Publicado: (2022)

Meta-analysis of active tuberculosis gene expression ascertains host directed drug targets
por: Ponnusamy, Nirmaladevi, et al.
Publicado: (2022)

A decade of progress: bibliometric analysis of trends and hotspots in oral microbiome research (2013-2022)
por: Li, Zhengrui, et al.
Publicado: (2023)

Discovery of Benzopyrrolizidines as Promising Antigiardiasic Agents
por: Auriostigue-Bautista, Juan Carlos, et al.
Publicado: (2022)

Conditional Silencing by CRISPRi Reveals the Role of DNA Gyrase in Formation of Drug-Tolerant Persister Population in Mycobacterium tuberculosis
por: Choudhary, Eira, et al.
Publicado: (2019)

Trypanosoma cruzi-specific CD8(+) T cells and other immunological hallmarks in chronic Chagas cardiomyopathy: Two decades of research
por: Puerta, Concepción J., et al.
Publicado: (2023)

Transcriptional Profile of Mycobacterium tuberculosis in an in vitro Model of Intraocular Tuberculosis
por: Abhishek, Sudhanshu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_935lp3dvl31fcn651nqvns0a4h